Mobile

Open-label, multicenter, dose-escalation Phase I/II study to evaluate safety, pharmacokinetics and activity of RO5126766, a dual Raf and MEK inhibitor, administered orally as monotherapy in patients w...

Update Il y a 4 ans
Reference: EUCTR2008-002298-11

Open-label, multicenter, dose-escalation Phase I/II study to evaluate safety, pharmacokinetics and activity of RO5126766, a dual Raf and MEK inhibitor, administered orally as monotherapy in patients with advanced tumors

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Part I of the study (Dose Escalation): - To determine the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicities (DLT) of RO5126766 administered on an oral continuous daily schedule. Part II of the study (Expansion Cohort): - To investigate RO5126766 single agent activity in patients with metastatic or advanced solid tumor.

Inclusion criteria

  • To investigate RO5126766 single agent activity in patients with metastatic or advanced solid tumor

Links